MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program
- PMID: 38891870
- PMCID: PMC11172132
- DOI: 10.3390/ijms25115684
MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program
Abstract
The Diabetes Prevention Program (DPP) randomized controlled trial demonstrated that metformin treatment reduced progression to type 2 diabetes (T2D) by 31% compared to placebo in adults with prediabetes. Circulating micro-ribonucleic acids (miRs) are promising biomarkers of T2D risk, but little is known about their associations with metformin regimens for T2D risk reduction. We compared the change in 24 circulating miRs from baseline to 2 years in a subset from DPP metformin intervention (n = 50) and placebo (n = 50) groups using Wilcoxon signed rank tests. Spearman correlations were used to evaluate associations between miR change and baseline clinical characteristics. Multiple linear regression was used to adjust for covariates. The sample was 73% female, 17% Black, 13% Hispanic, and 50 ± 11 years. Participants were obese, normotensive, prediabetic, and dyslipidemic. Change in 12 miR levels from baseline to 2 years was significantly different in the metformin group compared with placebo after adjusting for multiple comparisons: six (let-7c-5p, miR-151a-3p, miR-17-5p, miR-20b-5p, miR-29b-3p, and miR-93-5p) were significantly upregulated and six (miR-130b-3p, miR-22-3p, miR-222-3p, miR-320a-3p, miR-320c, miR-92a-3p) were significantly downregulated in the metformin group. These miRs help to explain how metformin is linked to T2D risk reduction, which may lead to novel biomarkers, therapeutics, and precision health strategies.
Keywords: diabetes prevention program; diabetes risk; metformin; microRNA; post-transcription.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Update of
-
MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.Res Sq [Preprint]. 2024 Jan 16:rs.3.rs-3846347. doi: 10.21203/rs.3.rs-3846347/v1. Res Sq. 2024. Update in: Int J Mol Sci. 2024 May 23;25(11):5684. doi: 10.3390/ijms25115684. PMID: 38313262 Free PMC article. Updated. Preprint.
Similar articles
-
MicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program.Res Sq [Preprint]. 2024 Jan 16:rs.3.rs-3846347. doi: 10.21203/rs.3.rs-3846347/v1. Res Sq. 2024. Update in: Int J Mol Sci. 2024 May 23;25(11):5684. doi: 10.3390/ijms25115684. PMID: 38313262 Free PMC article. Updated. Preprint.
-
Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization.Diabetes Care. 2014;37(5):1375-83. doi: 10.2337/dc13-1847. Epub 2014 Jan 29. Diabetes Care. 2014. PMID: 24478399 Clinical Trial.
-
Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: Moving towards precision health for diabetes prevention.Metabolism. 2015 Sep;64(9):1051-9. doi: 10.1016/j.metabol.2015.05.013. Epub 2015 May 28. Metabolism. 2015. PMID: 26031505 Free PMC article.
-
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.Diabetologia. 2017 Sep;60(9):1601-1611. doi: 10.1007/s00125-017-4361-9. Epub 2017 Aug 2. Diabetologia. 2017. PMID: 28770322 Free PMC article. Review.
-
Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2077-90. doi: 10.1161/ATVBAHA.111.241893. Arterioscler Thromb Vasc Biol. 2012. PMID: 22895669 Free PMC article. Review.
Cited by
-
Metabolomic Signatures in Adults with Metabolic Syndrome Indicate Preclinical Disruptions in Pathways Associated with High-Density Lipoprotein Cholesterol, Sugar Alcohols.Res Sq [Preprint]. 2025 Feb 14:rs.3.rs-5989567. doi: 10.21203/rs.3.rs-5989567/v1. Res Sq. 2025. PMID: 39989952 Free PMC article. Preprint.
-
New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine.Eur J Med Res. 2025 Jun 4;30(1):450. doi: 10.1186/s40001-025-02682-5. Eur J Med Res. 2025. PMID: 40468398 Free PMC article. Review.
-
Integrated Network Analysis Decipher ZNF384-Related miR-20b-5p and miR-424-5p in Colon Adenocarcinoma.Cancer Rep (Hoboken). 2025 May;8(5):e70233. doi: 10.1002/cnr2.70233. Cancer Rep (Hoboken). 2025. PMID: 40405535 Free PMC article.
-
miR-92a-3p and miR-182-3p as potential biomarkers for the differential diagnosis of gestational diabetes mellitus and its correlation with pregnancy outcomes.Ir J Med Sci. 2025 Jun;194(3):909-916. doi: 10.1007/s11845-025-03953-0. Epub 2025 Apr 10. Ir J Med Sci. 2025. PMID: 40208476
-
The expression of insulin signaling and N-methyl-D-aspartate receptor genes in areas of gray matter atrophy is associated with cognitive function in type 2 diabetes.medRxiv [Preprint]. 2025 Apr 1:2025.03.26.25324696. doi: 10.1101/2025.03.26.25324696. medRxiv. 2025. Update in: J Alzheimers Dis. 2025 Aug 13:13872877251364906. doi: 10.1177/13872877251364906. PMID: 40236395 Free PMC article. Updated. Preprint.
References
-
- Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; Atlanta, GA, USA: 2020.
-
- Aroda V.R., Knowler W.C., Crandall J.P., Perreault L., Edelstein S.L., Jeffries S.L., Molitch M.E., Pi-Sunyer X., Darwin C., Heck-man-Stoddard B.M., et al. Metformin for diabetes prevention: Insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–1611. doi: 10.1007/s00125-017-4361-9. - DOI - PMC - PubMed
-
- Diabetes Prevention Program Research Group Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42:601–608. doi: 10.2337/dc18-1970. - DOI - PMC - PubMed
-
- Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M., Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403. doi: 10.1056/NEJMoa012512. - DOI - PMC - PubMed
-
- Madsen K.S., Chi Y., Metzendorf M.-I., Richter B., Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2019;12:CD008558. doi: 10.1002/14651858.CD008558.pub2. - DOI - PMC - PubMed